Investigational Drug Information for Resiniferatoxin
✉ Email this page to a colleague
What is the development status for investigational drug Resiniferatoxin?
Resiniferatoxin is an investigational drug.
There have been 10 clinical trials for Resiniferatoxin.
The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2021.
The most common disease conditions in clinical trials are Osteoarthritis, Knee, Osteoarthritis, and Pain, Intractable. The leading clinical trial sponsors are Sorrento Therapeutics, Inc., National Institute of Neurological Disorders and Stroke (NINDS), and National Institute of Dental and Craniofacial Research (NIDCR).
There are one hundred and twenty-three US patents protecting this investigational drug and zero international patents.
Summary for Resiniferatoxin
| US Patents | 123 |
| International Patents | 3,012 |
| US Patent Applications | 698 |
| WIPO Patent Applications | 467 |
| Japanese Patent Applications | 433 |
| Clinical Trial Progress | Phase 1 (2021-04-01) |
| Vendors | 19 |
Recent Clinical Trials for Resiniferatoxin
| Title | Sponsor | Phase |
|---|---|---|
| Phase I Open Label Clinical Trial Using Resiniferatoxin, A Non-Opioid Medication, for the Management of Refractory Morton's Neuroma Pain | National Institutes of Health Clinical Center (CC) | Phase 1 |
| Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain | National Institute of Neurological Disorders and Stroke (NINDS) | Phase 1/Phase 2 |
| Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer | Sorrento Therapeutics, Inc. | Phase 2 |
Clinical Trial Summary for Resiniferatoxin
Top disease conditions for Resiniferatoxin
Top clinical trial sponsors for Resiniferatoxin
US Patents for Resiniferatoxin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Resiniferatoxin | ⤷ Sign Up | Compositions and methods for treating rebound erythema associated with topical alpha-adrenergic agonists | Scherer; Warren (Lutz, FL) | ⤷ Sign Up |
| Resiniferatoxin | ⤷ Sign Up | Pharmaceutical formulation containing irritant | Purdue Pharma L.P. (Stamford, CT) | ⤷ Sign Up |
| Resiniferatoxin | ⤷ Sign Up | Pharmaceutical products | Purdue Pharma L.P. (Stamford, CT) | ⤷ Sign Up |
| Resiniferatoxin | ⤷ Sign Up | Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders | OTONOMY, INC. (San Diego, CA) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) | ⤷ Sign Up |
| Resiniferatoxin | ⤷ Sign Up | Azaspiro derivatives as TRPM8 antagonists | RaQualia Pharma Inc. (Aichi, JP) | ⤷ Sign Up |
| Resiniferatoxin | ⤷ Sign Up | Compostions and methods for diagnosis of axial pain with or without radiculopathy | Warsaw Orthopedic, Inc. (Warsaw, IN) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Resiniferatoxin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Resiniferatoxin | World Intellectual Property Organization (WIPO) | WO2017132214 | 2036-01-26 | ⤷ Sign Up |
| Resiniferatoxin | Australia | AU2002319774 | 2021-08-06 | ⤷ Sign Up |
| Resiniferatoxin | Brazil | BR0212019 | 2021-08-06 | ⤷ Sign Up |
| Resiniferatoxin | Brazil | BR0212020 | 2021-08-06 | ⤷ Sign Up |
| Resiniferatoxin | Canada | CA2455420 | 2021-08-06 | ⤷ Sign Up |
| Resiniferatoxin | Canada | CA2456322 | 2021-08-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
